Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.
Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, UK.
M J
MJ
Brown
J E
JE
Dickerson
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage; D004311:Double-Blind Method; D017292:Doxazosin; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D002216:Captopril; D017292:Doxazosin; D011224:Prazosin